Ipertensione arteriosa polmonare: stima della casistica italiana e considerazioni sull’impatto sul budget dell’introduzione di tadalafil

Ipertensione arteriosa polmonare: stima della casistica italiana e considerazioni sull’impatto sul budget dell’introduzione di tadalafil

Authors

  • Luca Guidi Health Outcomes research, Eli Lilly Italia S.p.A

  • Mariano Alejandro Mignini Eli Lilly Intensive Care Regional Europe



DOI:

https://doi.org/10.7175/fe.v11i2.185

Keywords:

Pulmonary arterial hypertension, Tadalafil, Budget impact

Abstract

This contribution is an attempt to estimate a range of Pulmonary Arterial Hypertension (PAH) prevalence in Italy using international literature and Italian drug market sales data and to evaluate the budget impact of the introduction of tadalafil among the actual drugs with specific indication for this pathology. The final epidemiological figure obtained shows a wide range of prevalence of PAH in Italy (900-3,000 cases). The introduction of tadalafil as PAH treatment should not cause a cost increase for the pharmaceutical budget considering that this new therapy will occupy essentially the patient segment actually treated with sildenafil and that it reduces, in a significant number of patients, the daily cost of PAH therapy through a stable, fixed dose, administration.

Downloads

Published

2010-06-15

How to Cite

Guidi, L., & Mignini, M. A. (2010). Ipertensione arteriosa polmonare: stima della casistica italiana e considerazioni sull’impatto sul budget dell’introduzione di tadalafil. Farmeconomia. Health Economics and Therapeutic Pathways, 11(2), 77–82. https://doi.org/10.7175/fe.v11i2.185

Issue

Section

Original research

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Loading...